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Ethylene oxide (EO) is a well-known sterilizing agent. However, only recently has its use significantly emerged, based on its range
of applications in the field of new medical device development and sterilization. This paper describes the progress in terms of EO
sterilization and concludes that it remains a promising field to explore and develop. The EO action mechanism and toxicity are
analyzed, and a critical analysis is made on how it is possible to use EO sterilization for medical devices advantageously, with em-
phasis on cycle design and validation. One huge challenge is related with the development of mathematical models to integrate
lethality to allow a continuous increase of process flexibility, without compromising its safety. The scientific community should
also focus on other important issues, such as EO diffusion in different substrates, taking into account different environmental con-
ditions both for sterilization and aeration. (Am J Infect Control 2007;35:574-81.)The field of medical sterilization has become in-
creasingly complex because of the need to prevent
patient exposure to infections caused by organisms
on instruments and devices used during their care.
Failures in adequate sterilization of medical devices
(MDs) result in significant institutional costs related to
patient nosocomial infections and mortality/morbidity
concerns.1,2
The more widely used industrial MDs sterilization
technologies are steam, ethylene oxide (EO), and g
and electron beam irradiation. There are other methods
under development, such as low-temperature hydrogen
peroxide gas plasma, low-temperature peracetic acid
gas plasma, vapor-phase hydrogen peroxide, ozone,
chlorine dioxide, and high-intensity visible light.2-5
EO has emerged as the sterilization method of
choice for MDs because of its undeniable advantages
compared with other technologies, which will be dis-
cussed in more detail. EO is an exceptional sterilizing
agent because of its effective bactericidal, sporicidal,
and virucidal activity. However, difficulties had to be
overcome, mostly related with potential hazards of
EO to patients, staff, and environmental, as well as
risks associated with handling a flammable gas.1,2,6-8
EO has allowed and contributed significantly to the
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Porto, Portugal. E-mail: clsilva@esb.ucp.pt.advancement and evolution of delicate, complex, and
sophisticated MDs that otherwise would not be avail-
able because, for sensitive materials, EO is the only
acceptable sterilization method.2,6 EO sterilization
has become even more important since the single-
use MD market has grown, and, with the purpose of
cost saving in health management, there has been a
transition to presentation of MDs in customized packs
for use in specific medical and surgical procedures.
The diversity of developed products, designs, types of
materials, and packaging configurations resulted in
an exponential growth of EO sterilization and made
this method the most widely used MD sterilization
technology, with a continuous growth tendency. Today,
EO sterilization is described as the most cost-effective,
low-temperature sterilization process available, with a
recognized history of reliability.6-11
The aim of this paper is to summarize the informa-
tion available on EO sterilization, and to present critical
points of view about what has been done and is re-
quired, to provide the tools for advancement and opti-
mization of EO sterilization of MDs. The present article
provides a 4-part comprehensive review in the context
of EO sterilization of MDs. The first part presents an
overview of the EO activity mechanisms and inherent
toxicity of the sterilizing agent. The second part summa-
rizes the advantages of this sterilization technology over
the other 2 industrial sterilization technologies most
widely used. The objective is to explain why EO, despite
many predictions about its demise as a sterilization
alternative, still is a dominant mode of sterilization
and continues to be used for increasing volumes of MDs.
The third part outlines the process design and
process validation procedures, including the microbio-
logic validation, which is the most challenging in the
context of validation. Finally, the last part addresses
the state-of-the-art on optimization of EO sterilization
conditions. Recently updated and very promising
issues, such as parametric release, lethality, and EO
diffusion modelling, are discussed.
EO STERILIZATION MECHANISM AND TOXICITY
EO sterilization mechanism
The EO high reactivity, as expressed by the high en-
ergy of its exergonic combustion reaction, in combina-
tion with its high diffusivity, is of major importance for
the inactivation of microorganisms.12,13 EO is a direct
alkylating agent that does not require metabolic activa-
tion, and its microbiologic inactivation properties are
considered to be the result of its powerful alkylation
reaction with cellular constituents of organisms, such
as nucleic acid and functional proteins, including
enzymes, which leads to consequent denaturation.
The addition of alkyl groups to proteins, DNA, and
RNA in microorganisms by binding to the sulfhydryl
and hydroxyl, amino, and carboxyl groups, prevents
normal cellular metabolism and ability to reproduce,
which render affected microbes nonviable.1,12,14-17
These chemical moieties are not present in most of
the MDs composition; therefore, exposure to EO does
not cause them similar structural changes.5,18
EO toxicity
Taking into account the previously described EO
sterilization action mechanism, it is easy to understand
EO toxicity as a chemical agent and potential related
problems with employee, patient, and environmental
safety.
EO toxicity in the workplace
The ability of a chemical to serve as an alkylating
agent, and to cause mutations in a variety of biologic
test systems, is widely accepted as an indicator that
the chemical may have carcinogenic potential. Both
alkylation and mutagenicity potential have been dem-
onstrated for EO.19,20
However, nowadays, EO can be used safely, with
minimal personal risk of chemical hazardous ex-
posure, by following recommended practices and
meeting current Occupational Safety and Health
Administration EO regulations.9 Despite the discus-
sions about EO potential risk, this sterilant is being
used with greater frequency, especially because of in-
vestments made on equipment that have dramatically
improved the efficiency of the process and make it pos-
sible to meet concerns over worker exposure. The pro-
cess equipment of modern plants generally consists
of tightly closed, highly automated, and controlled
systems.1,2,7,21EO toxicity in sterilized MDs:
control of residues
In addition to the problems associated with EO toxicity
in the workplace, it is also important to take into consid-
eration the EO and its secondary product residuals and
toxicity on sterilized MDs. EO and some of its derivates,
such as ethylene chlorohydrin, which appears when
chloride ions are present, and ethylene glycol, formed
by EO reaction with water, are toxic residues.14,22-24
Taking into consideration the diversity of MDs steril-
ized with EO, and the potential undesirable effect on
patient health, residue control is required. The accurate
determination of residues is also critical for the de-
velopment of reliable risk assessment data used by
toxicologists, epidemiologists, MD manufacturers, and
regulatory bodies.25
The series of standards governing the biologic test-
ing of MDs include the International Organization for
Standardization (ISO) 10993-7 (Biological Evaluation
of MDs—Ethylene Oxide Sterilization Residuals),
which specifies the allowable limits of EO and ethylene
chlorohydrin by categorization of products based on
examination of toxicologic risk of the residue to the
patient, according to the length of the time the patient
is likely to be exposed to the device.26
Just as EO diffusivity has been a well-studied field,
so, then, MD design, including the selection of mate-
rials that will follow EO sterilization, can be done in a
similar logical way. Moreover, investigations about the
efficacy of different aeration methods are required.
Different aeration technologies have been reported,
such as pulsed vacuums postprocess and heat addition,
steam addition, and removal, as well as combinations
of different gases and pressure set points and newer
developments, such as microwave desorption. Despite
the major interest on this issue, there are no recently
published studies about efficiency comparisons for
the different aeration technologies.27
EO STERILIZATION AND ITS SPECIFIC
ADVANTAGES
The compatibility of EO with a wide range of mate-
rials and its chemical molecule penetration properties
in not so aggressive environments, compared with dry
heat or steam, made EO sterilization the most suitable
process for the majority of heat- and/or moisture-
sensitive medical products.20,28
The effectiveness of EO sterilization, coupled with
the flexibility of the process allowed by the large num-
ber of possible control variables, represents some of
the advantages of this method.1,7-10,12,18 Taking into
consideration the thermal or moisture sensitivity of
the specific material, the parameters of the EO cycle
can be adjusted to preserve the integrity of the device.
Steam and g irradiation sterilization frequently
cause polymers degradation and changes in physical
or mechanical properties, which can be detrimental
for intended performance.29-31 Many MDs are com-
posed of heat-sensitive materials. Regarding g irradia-
tion, generation of free radicals through hemolytic
bond cleavage occurs because 60Co sources supply
1.17 and 1.33 MeV photon energies, which correspond
to 5 orders of magnitude larger than the average energy
of a chemical bond.28,32-36
The opinion of some sterilization specialists on new
developments in the MDs sterilization techniques that
use oxidizing agents such as hydrogen peroxide, ozone,
peracetic acid, and chlorine dioxide is that limited
development will occur because of inherent adverse
effects on material properties.4
FROM PROCESS DESIGN TO MARKET RELEASE
OF EO STERILIZED MD
Process design includes the planning of the physical
parameter conditions (such as temperature, humidity,
and EO concentration) of a sterilization process, taking
into consideration the limitations imposed by the
product, the sterile barrier packaging, and the equip-
ment.37 The efficiency and profitability of the process,
the personnel safety, and the equipment integrity as
well as the well-being of the end user of EO-sterilized
MDs are all directly related to the cycle design. Regard-
ing efficiency, the influence of each of the EO steriliza-
tion process parameters on reaction kinetics should be
considered when a cycle design is being conducted.
Modelling of accumulated lethality and EO diffusion
kinetics are 2 important issues that will be further dis-
cussed in more detail.
The sterilization process must consistently assure
that all critical process parameters are delivered within
the load, to a degree that assures the required sterility
assurance level, without causing any deleterious effect
on product and its sterile barrier package functionality
and safety.37-39 These activities are part of the process
validation, which includes physical and microbiologic
performance qualifications.
The release of the MDs to the market is done accord-
ing to the process specifications defined during valida-
tion. There are 2 methodologies for market release of
MDs: conventional and parametric. The conventional
traditional method of release requires that the process
parameters are within the validated tolerance and that
the biologic indicators (BIs) exposed to the sterilization
process are inactivated. On the other hand, parametric
market release relies solely on the recording and eval-
uation of the process parameters because the equip-
ment potentialities are enough to evaluate the impact
of process parameters on microbiologic inactivation.39Parametric release is still a very challenging topic and
will be further discussed in more detail. A well-struc-
tured process design, its rigorous validation, and strict
and efficient control of the sterilization cycle parame-
ters are the key principles for the safe and efficacious
release of the MDs to the market.
Process design
Investigation of all process variables impact is man-
datory for reaching a well-structured EO sterilization
process. Furthermore, considerations about product
compatibility together with optimization of the sterili-
zation process should be undertaken.
The lethality of EO sterilization depends on the
following 4 process parameters: (1) EO concentration,
(2) exposure time, (3) temperature, and (4) humid-
ity.1,10,37,40 The increase of EO concentration within
certain limits results in extended microbial inactivation
and exposure time decrease.1,10 Heider et al40 found a
first-order kinetics behavior across the entire concen-
tration range, from 50 to 1200 mg/L. In the past, concen-
trations of EO up to 1200 mg/L were common, whereas,
today, EO concentrations of even less than 300 mg/L are
being used.5,40 A progressive decrease of EO concentra-
tion levels have been verified, which results in shorter
aeration periods after sterilization and additional envi-
ronmental, health, and safety benefits.
Temperature is an extremely important parameter
affecting microbial lethality.40,41 Table 1 presents pub-
lished Q10 and related z-values. A consensus seems to
have involved a Q10 value of 2, which means that a
108C change would affect lethality by a factor of 2.
Environmental humidity appears to be another criti-
cal variable; however, there were always differing opin-
ions about the required optimum relative humidity
(RH).13,42,43 Most of the recent studies indicate that,
within the limits of 30% to 90%, the RH does not influ-
ence lethality. Sterilization efficacy decreases markedly
below 30% and above 90% because RH is critical for the
EO diffusivity into devices and microbes.10,13,41 Heider
et al40 found a correlation between the reaction kinetics
rate and the RH in the 10% to 60% range, whereas no
further changes were observed at higher levels. Accord-
ing to this, it is recommended to ensure a RH of more
than 60% so that the effectiveness of the sterilization
process is not compromised. Although, nowadays, it is
considered that the RH effect is constant if the parame-
ter is within the limits of 30% to 90%, additional studies
should be further performed to assure the true veracity
of this information.10
Besides the EO sterilization process parameters
influence on process design, other variables, such
as natural bioburden, device/package properties, load
density, and configuration in which the specific MD is
included for sterilization, should be considered. Within
the device/package properties, the raw material com-
position, materials diffusion properties, sensitivity to
both negative and positive pressure changes, and max-
imum allowed heat and moisture as well as chemical
tolerance to EO should be analyzed.10,40,41
Process validation
The validation of EO sterilization processes, which
includes physical and microbiologic performance
qualification, is described in detail in ISO44 11135 and
European Norm (EN)45 550. However, none of these
norms include guidance for the selection of a steriliza-
tion process challenge device to be used as representa-
tive worst case matrix. Manufacturing conditions,
construction materials, and product design, including
materials geometric variability and packaging charac-
teristics, are among the factors that need to be consid-
ered. However, the way to relate all these variables is
a great challenge for the sterilization specialist. The
physical performance qualification allows the verifica-
tion of the cycle reproducibility, as well as evaluation
of the cycle impact on the product, packaging function-
ality, and safety.39
The purpose of microbiologic validation is to assess
the microbiologic lethality of the sterilization pro-
cess.38,46 The above referred international and Euro-
pean norms provide different approaches for carrying
out microbiologic performance qualification and will
be described in more detail.44,45
Microbiologic validation
There are 3 microbiologic approaches for process
definition, which are by decreasing order of utilization:
• Overkill method;
• combined biologic indicator/bioburden method; and
• bioburden method.
The overkill approach uses BI data to assess the
microbial inactivation rate for a given process. The
process definition based on ‘‘Combined biological
indicator (BI)/bioburden method’’ defines the treatment
extent required to achieve the specified sterility
Table 1. Effect of temperature on EO inactivation—Q10
and related z-values
Reference Q10 z-value (8C)*
Ernest55 1.8 39.2
Plug et al56 1.90 36.0
Bruch57 and Lui58 2.19 29.4
Phillips and Miller13 2.21 29.0
*z5 108ClogQ10.assurance level from knowledge of the BIs inactivation
and of the product bioburden population to be steril-
ized. The ‘‘Bioburden method’’ is a process definition
based on inactivation of the microbial population in
its natural state.47
The overkill method is applicable as long as the
combination of population (106 microorganisms of
Bacillus subtilis niger, reclassified in 2001 by Fritze
and Rudiger48 as Bacillus atrophaeus) and resistance
of the BI, expressed as D-value, exceeds that of the
product bioburden. The sterilization process definition
based on this approach is often conservative because
necessary sterilization cycle parameters are signifi-
cantly higher than those required to kill product bio-
burden. Cycle lethality determination can be obtained
from the half-cycle method, which consists of deter-
mining the minimum time of exposure at which there
are no survivors from tested BIs. According to this
method, at least a 6-log reduction in population of
microorganisms is demonstrated for the BI organism
in the half cycle. Using the same process parameters,
except exposure time, full sterilization cycle achieves
at least a 12-log reduction by doubling the half-cycle
time. No D-value calculations are performed, and, be-
cause of its simplicity, as well to the robust sterility as-
surance level that is achieved, this is probably the most
popular approach.1,10,38,40,44,45,47-49 The advantage of
the other 2 microbiologic approaches, combined BI/
bioburden method and bioburden method, is a reduc-
tion in cycle exposure time and, consequently, the pro-
duct exposure to the sterilizing agent is minimized.
The combined BI and bioburden method requires
a low population of the product bioburden and the
microorganism’s resistance to be known, as well as a
high level of confidence that the bioburden data are
representative of ‘‘worst case conditions.’’ The process
definition based on the bioburden method requires
extensive testing during the development phase and
routine processing. It requires a validated bioburden
recovery method and identification of the microorgan-
isms that are typically found in or on the routine pro-
duct, as well as more exigent environmental and
manufacturing process control. Furthermore, it is nec-
essary to carry out fractional exposure cycles on a reg-
ular basis to support the continued effectiveness of the
sterilization process. Despite the extensive work that
the bioburden method requires, it may be a require-
ment if there is a reason to believe that the MD may
be contaminated with microorganisms more resistant
than the BI.10,38,39,47,49
Besides the half-cycle method, there are 2 other
commonly used methods for estimating or calculating
cycle lethality: the survivor curve method and the
fraction-negative method. The survivor curve con-
struction method calculates cycle lethality based on
enumeration of survival microorganisms, and the
fraction-negative method uses growth/no growth data
from the sterility tests.
The survivor curve construction is performed by
counting microbiologic survivors in terms of colony-
forming units, recovered after exposing the microbio-
logic population to sublethal sterilizing cycles of graded
exposures of EO, with all other parameters except time
remaining constant. The survivor curve construction
should include at least 5 points, imposing increasing
exposure times to EO, and the resulting data give the
EO exposure time required to achieve a particular prob-
ability of survival of the test organism.38,44,50
The fraction-negative method is also carried out
by exposing BIs to sublethal cycles, but the analysis
is done to growth/no growth data from the sterility
tests.44,49,50 The exposure time required to achieve a
specified survival probability of the test organism is
calculated from the D-value, using the limited Spear-
man-Karber procedure, which is the common refer-
ence method for international standards. However,
there are other commonly used statistical methods,
such as the Holcomb-Spearman-Karber procedure,
the Stumbo-Murphy-Cochran procedure, or the limited
Stumbo-Murphy-Cochran procedure, which can be
used under particular conditions,38,50 although an
ISO meeting suggested that the Stumbo-Murphy-
Cochran procedure was less accurate than the limited
Spearman-Karber procedure, and the ISO recommen-
ded abandoning the Stumbo-Murphy-Cochran proce-
dure. However, according to Shintani et al,51 the
Stumbo-Murphy-Cochran procedure is not less accu-
rate than the limited Spearman-Karber procedure. In
fact, the Stumbo-Murphy-Cochran procedure seems
superior to the limited Spearman-Karber procedure
with the proposed restriction (ie, n$ 50, r$ 1, r/n, 0.9,
where n is the number of BIs and r the number of neg-
ative BIs).
Because of its major simplicity, the half-cycle
method is more popular than the fraction-negative
method, and the least popular is the construction of
the survivor curve. However, according to the present
regulatory remarks, the microbiologic qualification of
a parametric release sterilization, which will be ex-
plained later in more detail, should not use the half-
cycle method because of the fact that it does not
provide sufficient information on lethality kinetics.44
EO STERILIZATION PROCESS OPTIMIZATION
Optimization of EO sterilization processes is a
challenge because of the fact that the global com-
petition market requires cost-effectiveness, flexibility,
and inherent reduction of overall sterilization process
time while continuing to comply with regulatoryrequirements and product quality.8,9,11 Traditionally,
most of the EO sterilization production time is taken
up with 2 operations, which are when products are
held waiting for the microbiologic test results and/or
for the validated aeration time to ensure residues levels
in compliance with the requirements of ISO 10993-7.26
Implementation of parametric release simply eliminates
the microbiologic test phase from routine.8,9,11,44,45,52
Validation of not only sterilization but also the aera-
tion process, with consequent assessment of EO res-
idues in compliance with the requirements of ISO
10993-7,26 has allowed a reduction in processing
time. Furthermore, to get a reduction on EO residuals
after sterilization, research in the field of EO diffusion
is required. Investigations about comparative efficien-
cies among different ways of carrying aeration are
also lacking.8,9,11
To shorten production time, a joint study involving
sterilization and aeration processes limits shall be per-
formed. Direct measurement of key process variables,
as well as improvements in process design achieved
through scientific modelling and experimental evi-
dence, allows development of each process phase
and consequent reduction in an overall sterilization
process time. EO sterilization process optimization
will be explained below in more detail under 3 main
topics: parametric release, lethality modelling, and
EO diffusion modelling.
Parametric market release
Parametric market release is the declaration of pro-
duct sterilization adequacy based solely on measure-
ment and evaluation of physical process parameters
compliant with previously validated parameters.8,39,44,45
The main difference between parametric and conven-
tional release is the number of process parameters
directly measured. According to ISO44 11135 and
EN45 550 requirements, for conventional release
compliance, the parameters that should be directly
measured are the time of each phase, the pressure
throughout the process, and the headspace tempera-
ture. The remaining two critical parameters, humidity
and EO concentration, can be quantified indirectly
by thermodynamic calculation based on pressure
rise and temperature. Acceptance of the 2 indirectly
measured parameters is supported by the negative
growth of the exposed BIs. According to conventional
release procedure, the BIs data integrate and confirm
that appropriate levels of heat, water vapor, and EO
concentrations have been delivered to the load, as
demonstrated during microbiologic validation of the
process.11,44,45
The philosophy of parametric release is that once
a cycle is validated, using direct analysis of all critical
process parameters and distribution of microbiologic
indicators, the resulting data can be used to define sci-
entifically the approved physical limits of each of the
process parameters.44,45 Parametric release is, from a
scientific point of view as well as from a strategic pro-
duction standpoint, the preferred choice. In compari-
son with conventional release, the more thoroughly
monitored process parameters give further under-
standing and stricter sterilization process control,
simultaneously reducing costs and bringing a signifi-
cant flexibility to the process.8,11,44,45,52
Lethality modelling
The scientific modelling of the EO sterilization cycle
allows the definition of optimal microbiologic inactiva-
tion conditions. The prediction of accurate D-values
and process times, necessary to achieve the target
sterility assurance level, allows to reduce cycle times
and/or EO concentration and the comparison of effec-
tiveness and equivalency of different sterilization
processes. Furthermore, the lethality modelling con-
tributes to the process efficiency and flexibility, and
the industrial movement toward parametric release is
much more scientifically supported.10,40,53
To integrate mathematically the dynamic tempera-
ture and concentration conditions effects on inactiva-
tion, Rodriguez et al42 developed the following model
for BI spores of Bacillus subtilis niger:
NðtÞ5 Nðt5 0Þ
e

kTR
Rt
0
CðtÞn10 TðtÞ2TRz dt
 ð1Þ
where C, EO concentration; C(t), EO concentration as a
function of time; k, rate constant; N, number of survi-
vors; N(t), number of survivors as function of time;
t, time; T, temperature; T(t), temperature as a function
of time; TR, reference temperature; n, exponent; and z,
temperature increase required to reduce the decimal
reduction time (D-value) by 90%.
The model was validated under the following condi-
tions: 15% to 90% RH, 200 to 1200 mg/L of EO gas, and
z-value of 29, 48C.42 The same authors also deduced
an expression for determining the accumulated le-
thality (equivalent process time) of an EO sterilization
process42:
FTR;CR;z5
1
CnR
Zt
0
CðtÞn10TðtÞ2TRz dt ð2Þ
where CR, reference EO concentration; F, exposure
time at TR and CR that would cause the same lethal ef-
fect as the T(t) and C(t) temperature regimes—equiva-
lent process time.Mosley et al10 criticized equation 2, referring that,
although it is mathematically correct, it is unusable
in the given format because of the fact that EO concen-
trations cannot be defined by any reasonable equation.
Although an n5 1 was suggested, no solution for n was
proposed.
Mosley et al10 enlarged the scientific modelling of
EO sterilization by deducing another mathematical ap-
proach that allows the calculation of equivalent time,
based on reference values for EO concentration (CR)
and temperature (TR), for different EO concentration
and/or temperature conditions:
FCR;TR 5

10logtTR
 C
CR
and,
logtTR 5 logtT1
ðT2TRÞ
z
ð3Þ
where tT, time at a given constant temperature T; and
tTR , time at reference temperature. The same investiga-
tors also developed another equation to determine
accumulated equivalent time, where conditions are
changing for EO concentration and/or temperature:
FCR;TR 5 +
n
i5 1
Fi5 +
n
i5 1

10½logtTi11zðTi2TRÞ
Ci
CR
ð4Þ
where i, process step, for which the EO concentration
and temperature are constant; and n, total number of
process steps.
According to Mosley et al,54 greater errors can be as-
sociated with calculated integrated lethalities for steam
processes because z-values are lower and more varia-
ble under steam sterilization.
The mathematical models above presented are es-
sential for designing EO sterilization processes. Optimi-
zation and validation of the different methodologies
are a requirement.
EO diffusion modelling
The study of EO diffusion from the sterilizer head-
space to the articles and through the articles is a chal-
lenge matter. Once well understood and defined,
efficiency comparison among different aeration meth-
odologies, and prediction of the dynamic distribution
of EO concentration within the load, with the purpose
to define the specific relationship between EO concen-
tration and process lethality as well as to diminish EO
residuals after sterilization, will be possible. However,
despite the interest of this kind of studies, investiga-
tions in this field are almost inexistent. Once the mod-
elling of accumulated lethality, as well as the modelling
of EO diffusion according to different matrices, is fully
comprehended, then new approaches for design, vali-
dation, and routine control of the EO sterilization
processes will occur.
FINAL REMARKS
EO sterilization is a key issue for current medical de-
vice designs, and a considerable amount of work con-
cerning this topic has been published. Experimental
evidence and scientific modelling have allowed signif-
icant improvements on each process phase, resulting
in overall reduction of sterilization process time, with-
out compromising the delivery of sterile and safe pro-
ducts to the market.
Further developments are needed in terms of under-
standing the microbiologic inactivation kinetics under
EO sterilization process conditions. In parallel, there
is much to be done to understand EO diffusion behav-
ior on different materials. The ability to predict the dy-
namic distribution of EO concentration within the load
being sterilized would allow the estimation of theoret-
ical sterilizing EO concentrations.
Comparison of effectiveness and equivalency of dif-
ferent aeration methodologies are also required. In the
same context, it is also critical that the development of
reliable risk-assessment analysis for EO and related
residuals mature.
In terms of speed to the market and despite the
great advances already achieved, EO sterilization
and its unique capabilities are still in progress. Re-
garding newer and future developments on MD ster-
ilization methodologies, it is essential to compare
them against the characteristics of an ideal low-
temperature (,608C) sterilant, which includes high
efficacy, rapid activity, strong penetrability, material
compatibility, nontoxicity, adaptability, ability to with-
stand an organic load, monitoring capability, and cost-
effectiveness.
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